177Lu-DOTA-EB-TATE
PreclinicalRadiopharmaceutical
177Lu-DOTA-EB-TATE is one of 43 therapeutic programs targeting Thyroid Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
210 competitors in Thyroid Cancer
#DrugCompanyPhaseTrials
1Nexavar
BayerPhase 3
Koselugo
AstraZenecaPhase 3
Glucophage
EMD SeronoPhase 3
Sutent
PfizerPhase 2
Iclusig
TakedaPhase 2
Iressa
AstraZenecaPhase 2
Stivarga
BayerPhase 2
Istodax
TevaPhase 2
Actos
TakedaPhase 2
Mektovi
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thyroid Cancer1 trial
Phase 1/2, Open-Label Study of the Safety, Dosimetry and Efficacy of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Not yet recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Preclinical·NCT06991738·18 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 177Lu-DOTA-EB-TATE. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Modality
- Radiopharmaceutical
- Highest Phase
- Preclinical[1]